Let's break down Caplin Point Laboratories (CAPLIPOINT) — from its financial performance to how the market is valuing the stock.
Caplin Point Revenue Trend
Year-over-year, Caplin Point Laboratories grew revenue by 14.4% — from ₹1,694 Cr in FY2024 to ₹1,937 Cr in FY2025.
On a 10-year view, revenue grew from ₹252 Cr to ₹1,937 Cr at a 22.6% CAGR. That kind of compounding is what separates the growth names.
A ₹1,937 Cr revenue base makes Caplin Point Laboratories a mid-sized name in the Indian pharmaceuticals sector.
Caplin Point Laboratories has posted revenue growth for 9 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,937 Cr | +14.4% |
| FY2024 | ₹1,694 Cr | +15.5% |
| FY2023 | ₹1,467 Cr | +15.5% |
| FY2022 | ₹1,269 Cr | +17.0% |
| FY2021 | ₹1,085 Cr | — |
View Caplin Point Laboratories's full 10-year revenue trend with CAGR analysis →
Caplin Point Profitability
The bottom line looked healthy: Caplin Point Laboratories posted net profit of ₹541 Cr in FY2025, 17.3% above FY2024.
The company squeezed out better margins in FY2025, with net margin at 27.9% versus 27.2% in FY2024.
Per-share earnings moved to ₹70.25 in FY2025 from ₹59.90 in FY2024.
Is Caplin Point Undervalued
Caplin Point Laboratories shares are currently trading at ₹2,566.10.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Caplin Point Shareholding Pattern
At 70.6%, the promoter stake has been flat for the past 4 quarters.
As of June 2026, FIIs own 5.8% of the company — down from 6.5% a year earlier.
The DII stake stands at 2.5% as of June 2026, versus 2.1% in the year-ago period.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 70.6% | 5.8% | 2.5% | 21.2% |
| Mar 2026 | 70.6% | 6.2% | 2.1% | 21.1% |
| Dec 2025 | 70.6% | 6.6% | 2.0% | 20.8% |
| Sep 2025 | 70.6% | 6.5% | 2.1% | 20.8% |
Track quarterly shareholding changes for Caplin Point Laboratories →
Caplin Point Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹32.08B at the end of FY2025, up 18.9% from ₹26.98B a year earlier.
Other Assets is the largest block at 24.0%, followed by Property, Plant & Equipment at 20.9% and Receivables at 19.7%.
Equity makes up 90.0% of liabilities and equity, with debt at 0.2% and operating liabilities at 9.9%. Over the year, debt is up 154.8% and equity is up 23.0%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 5.11B |
| Receivables | 6.32B |
| Inventories | 3.36B |
| Property, Plant & Equipment | 6.70B |
| Investments | 2.79B |
| Intangibles & Goodwill | 112.70M |
| Other Assets | 7.69B |
| Category | Value |
|---|---|
| Equity | 28.86B |
| Short-term Debt | 21.10M |
| Long-term Debt | 29.10M |
| Trade Payables | 2.18B |
| Other Liabilities | 988.60M |
Caplin Point Stock Analysis
What should investors take away from Caplin Point Laboratories's (CAPLIPOINT) latest numbers? Here's the summary.
Revenue of ₹1,937 Cr in FY2025, up 14.4% year-over-year.
Long-term revenue has been compounding at 22.6% annually over 10 years.
The company is profitable, with a net margin of 27.9% and net income of ₹541 Cr.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Caplin Point Laboratories's detailed profile on Craytheon.